NASDAQ:JAZZ
Jazz Pharmaceuticals plc Stock News
$120.42
-0.0900 (-0.0747%)
At Close: Mar 28, 2024
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
02:25pm, Wednesday, 13'th Mar 2024
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
11:46am, Thursday, 29'th Feb 2024
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
08:51pm, Wednesday, 28'th Feb 2024
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings
07:31pm, Wednesday, 28'th Feb 2024
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
06:20pm, Wednesday, 28'th Feb 2024
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS
10:21am, Friday, 23'rd Feb 2024
Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
05:00pm, Tuesday, 20'th Feb 2024
While many top cannabis stocks have existed for years, the U.S. market has warmed up to the cannabinoid sector only recently. About 40 states allow the use of cannabis, although not all permit its rec
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
04:15pm, Wednesday, 14'th Feb 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 20
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
11:31am, Thursday, 08'th Feb 2024
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
3 Biotech Stocks to Buy on the Dip: February 2024
07:35am, Wednesday, 07'th Feb 2024
Biotech investing is not for impatient investors. So why is it attractive to some investors?
Redx Pharma inks $880m deal with Jazz Pharma; will bank $10m immediately
02:46am, Wednesday, 07'th Feb 2024
Redx Pharma PLC (AIM:REDX) said it is sellling its KRAS inhibitor programme to Nasdaq-listed Jazz Pharma Inc in a deal with a headlne value of $880 million. Under the terms of the transaction, Redx w
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
12:03pm, Wednesday, 31'st Jan 2024
There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.
Updated View On Jazz Pharmaceuticals' 2025 Goals
03:17pm, Monday, 29'th Jan 2024
Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher,
Jazz Pharmaceuticals targets positive momentum in 2024, receives Outperform rating
03:40pm, Wednesday, 03'rd Jan 2024
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) received an Outperform rating and a target price of $160 from Baird, citing optimistic expectations for the company's performance in the coming year. Initiating